Ever Supreme Business Summary

Ever Supreme Bio Technology (6712.TWO) operates a high-margin, dual-engine business model centered on regenerative medicine, functioning as Taiwan’s largest cell therapy Contract Development and Manufacturing Organization (CDMO) while simultaneously advancing a proprietary clinical pipeline. The company generates primary revenue through specialized cell preparation and storage services for 19 collaborating hospitals, commanding a 32% domestic market share. Its research arm focuses on four core technology platforms—immune cell, stem cell, nanocapsule, and exosome—to develop allogeneic, "off-the-shelf" therapies. Key clinical assets include CAR001, a first-in-class HLA-G-targeted CAR-BiTE therapy for solid tumors, and UMSC01, an umbilical cord mesenchymal stem cell treatment for myocardial infarction and stroke. Within the competitive landscape, Ever Supreme maintains a dominant position in the Taiwan cell therapy sector relative to peers such as Medigen Biotechnology (6612.TW), MetaTech (6173.TW), and international allogeneic developers, leveraging its integrated hospital network to secure stable cash flow for its capital-intensive R&D initiatives. The company was founded in 2016 by Dr. Chang-Hai Tsai, a distinguished figure in the medical field who also serves as the Chairman of China Medical University (CMU) and its extensive healthcare system. This institutional pedigree provides Ever Supreme with a strategic advantage in clinical trial recruitment and hospital integration. The current leadership team is headed by Chairperson Liu Chu-Chi (Judy Liu) and General Manager (CEO) Huang Wen-Liang, both of whom possess extensive experience in biotechnology commercialization and regulatory navigation. Vice President Lee Yu-Cheng serves as the key spokesperson, overseeing corporate strategy and investor relations. The company’s board and investor base are deeply anchored by the China Medical University Hospital ecosystem, ensuring a robust pipeline of academic-to-industrial translational research and a stable foundation for its recent 2026 expansion into international CDMO collaborations and the acquisition of Shine Out Bio Technology.